|drug3530||Treatment As Usual Wiki||1.00|
|drug341||Attention Training Program Wiki||1.00|
|drug640||COVID-19 PCR and Serology Wiki||1.00|
|D001321||Autistic Disorder NIH||0.33|
|D000067877||Autism Spectrum Disorder NIH||0.30|
There is one clinical trial.
The Social ABCs is an evidence-based, developmentally informed, caregiver-mediated behavioural intervention for toddlers with suspected or confirmed Autism Spectrum Disorder (ASD). It is based on principles of Pivotal Response Treatment (PRT, grounded in Applied Behaviour Analysis), and responsive parenting. The two key targets of this program are functional verbal communication and positive caregiver-child affect sharing. This intervention takes place in the context of play and daily routines, and in all contexts is made to be fun, natural and motivating for the child. In both a pilot study and a recently completed randomized control trial, toddlers whose caregivers received training in the Social ABCs intervention showed significant gains in early language development (both responsivity and initiations), increased child smiling (mediated by parent smiling), and a trend toward increased social orienting (one important manifestation of social attention). Despite the social-communication benefits demonstrated through the Social ABCs, the research team is also motivated to foster the attentional abilities of toddlers with emerging ASD in response to compelling evidence that early attentional control abilities may play a central role in the emergence of ASD. Based on this knowledge, the current study targets not only social-communication challenges and affect sharing (as per the existing Social ABCs intervention), but also attentional control in toddlers with suspected or confirmed ASD. Using a structured, computerized attention-training protocol, this RCT evaluates the impact of supplementing the standard Social ABCs intervention with pre-intervention attentional control training.
Description: Reaction time in Gap-Overlap task (milliseconds)Measure: Improved Attentional Flexibility Time: Week 1 (baseline) and Week 6
Description: Percentage of correct trials in a computer-based attention task (%)Measure: Improved Attentional Control Time: Week 1 (baseline) and Week 6
Description: Percentage of intervals in which child is oriented to caregiver (%)Measure: Increased Social Orienting to Parent Time: Week 1 (baseline), Week 6, Week 18, and Week 30
Description: Percentage of intervals in which caregiver and child are smiling together (%)Measure: Increased Child Smiling Time: Week 1 (baseline), Week 6, Week 18, and Week 30
Description: Gains in proportion of appropriate child vocal responses, following a caregiver prompt (reported as percentage).Measure: Increased Child Responsivity to Parent Prompt Time: Week 1 (baseline), Week 6, Week 18, and Week 30
Description: Percentage of intervals during which parents demonstrate appropriate use of the Social ABCs techniques (%)Measure: Parent Fidelity of Implementation Time: Week 6, Week 18, and Week 30
Description: Standard score on the Mullen Early Learning Scale (SS)Measure: Receptive Language Time: Week 0 and Week 30
Description: Standard score on the Mullen Early Learning Scale (SS)Measure: Expressive Language Time: Week 0 and Week 30
Description: Frequency of joint attentions bids on the Mini Early Social Communication (#)ScalesMeasure: Joint Attention Time: Week 0 and Week 30
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports